Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034.
about
Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibitPemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomesPhase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over theUsp9x- and Noxa-mediated Mcl-1 downregulation contributes to pemetrexed-induced apoptosis in human non-small-cell lung cancer cellsAdvances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach.Metformin synergistic pemetrexed suppresses non-small-cell lung cancer cell proliferation and invasion in vitro.5,10-Methenyltetrahydrofolate synthetase activity is increased in tumors and modifies the efficacy of antipurine LY309887.Augmented expression of cardiac ankyrin repeat protein is induced by pemetrexed and a possible marker for the pemetrexed resistance in mesothelioma cells.Spatial alterations of De Novo purine biosynthetic enzymes by Akt-independent PDK1 signaling pathways.
P2860
Q24631090-7CA5C336-E7DF-4F18-B005-644508F91029Q26745422-B6FB0A97-F255-46E6-8E68-FDD6C869C7F7Q28346782-40BFC8C6-511E-40C7-A91F-E9ED51F371C0Q33720633-B20007AC-40CE-4519-B1D9-B03A4EAED8A9Q34007721-A2E3FCAE-8974-48DB-A953-E8F4E1D097A7Q35832903-E286C8C8-5BAD-423E-BC4A-309B232CCF94Q38674016-E86108DC-C8AE-417D-90F1-FA05B34407A2Q42286837-EB451C18-B6D4-419F-8D25-46C30365F9C8Q47162696-0ADEF520-BBD1-43F7-A2C9-F615CBD1B1B7Q52317693-D4EE84BC-1BC0-4703-863B-A42D7BB75297
P2860
Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Pharmacokinetic and pharmacody ...... ltransferase inhibitor AG2034.
@ast
Pharmacokinetic and pharmacody ...... ltransferase inhibitor AG2034.
@en
type
label
Pharmacokinetic and pharmacody ...... ltransferase inhibitor AG2034.
@ast
Pharmacokinetic and pharmacody ...... ltransferase inhibitor AG2034.
@en
prefLabel
Pharmacokinetic and pharmacody ...... ltransferase inhibitor AG2034.
@ast
Pharmacokinetic and pharmacody ...... ltransferase inhibitor AG2034.
@en
P2093
P1476
Pharmacokinetic and pharmacody ...... yltransferase inhibitor AG2034
@en
P2093
D G Priest
H L McLeod
J D Roberts
L J Paradiso
M A Collier
M A Zorbas
R H Powrie
P304
P407
P577
2000-07-01T00:00:00Z